Announcements
- argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
- argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
- argenx Appoints Ana Cespedes to Board of Directors
- argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- argenx to Present at Upcoming Investor Conferences
- argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
More ▼
Key statistics
As of last trade argenx SE (1AE:MUN) traded at 346.80, -11.96% below its 52-week high of 393.90, set on Aug 26, 2022.
52-week range
Markit short selling activity
Open | 346.80 |
---|---|
High | 346.80 |
Low | 346.80 |
Bid | 347.00 |
Offer | 348.60 |
Previous close | 341.60 |
Average volume | 8.10 |
---|---|
Shares outstanding | 55.47m |
Free float | 55.47m |
P/E (TTM) | -- |
Market cap | 19.57bn EUR |
EPS (TTM) | -16.28 EUR |
Data delayed at least 15 minutes, as of Feb 07 2023 07:04 GMT.
More ▼